A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program

Recently approved in Europe and Australia, the multi-component meningococcal B vaccine, 4CMenB (Bexsero ® , Novartis Vaccines and Diagnostics), contains three surface-exposed recombinant proteins (fHbp, NadA, and NHBA) and New Zealand strain outer membrane vesicles (NZ OMV) with PorA 1.4 antigenicit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs (New York, N.Y.) N.Y.), 2014-01, Vol.74 (1), p.15-30
Hauptverfasser:	O’Ryan, Miguel, Stoddard, Jeffrey, Toneatto, Daniela, Wassil, James, Dull, Peter M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Antigens Bacterial diseases Bacterial diseases of the nervous system. Bacterial myositis Biological and medical sciences Clinical Trials as Topic Disease Drug Administration Schedule Epidemics Human bacterial diseases Humans Infectious diseases Internal Medicine Medical sciences Medicine Medicine & Public Health Meningococcal Infections - immunology Meningococcal Infections - prevention & control Meningococcal Vaccines - administration & dosage Meningococcal Vaccines - adverse effects Meningococcal Vaccines - immunology Meningococcal Vaccines - therapeutic use Neisseria meningitidis Pharmacology/Toxicology Pharmacotherapy Proteins Review Review Article Surveillance Teenagers Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!